ACTINIUM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.87 USD | +4.73% |
|
+0.29% | +35.24% |
Chart calendar Actinium Pharmaceuticals, Inc.
6c72370f3e2b3fd736ad402d8ce7a.fOxDDxho0JrbFL3hg_edkKeX2x4CIXP_fctlfsQiffY.MYEGZUhYuuqoJJCPy6XkxNDAjHRBdwGMNac0DJ59SKAUpRo-aS7926Em3g~27e008f651cf50be9156dfc29bcaa208
Upcoming events on Actinium Pharmaceuticals, Inc.
Past events on Actinium Pharmaceuticals, Inc.
| 2024-04-13 | European Bone Marrow Transplant Society Meeting |
| 2024-02-24 12:45 pm | American Society for Transplantation and Cellular Therapy and CIBMTR Meeting - I-Apamistamab Improve |
| 2024-02-24 11:30 am | American Society for Transplantation and Cellular Therapy and CIBMTR Meeting - Targeted Myeloablativ |
| 2024-02-22 07:45 pm | American Society for Transplantation and Cellular Therapy and CIBMTR Meeting |
| 2023-12-10 09:00 pm | American Society of Hematology Meeting |
| 2023-12-10 | American Society of Hematology Meeting - Updated Results from Phase 1 Study of Targeted Radiotherapy |
| 2023-12-10 | American Society of Hematology Meeting - 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response |
| 2023-12-10 | American Society of Hematology Meeting - 131I-Apamistamab Effectively Achieved Durable Responses in |
| 2023-12-10 | American Society of Hematology Meeting - 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transpla |
| 2023-12-10 12:30 pm | American Society of Hematology Meeting |
| 2023-12-09 08:30 pm | American Society of Hematology Meeting |
| 2023-11-30 09:30 am | Annual General Meeting |
| 2023-11-05 | Bio-Europe Conference |
| 2023-11-04 12:00 pm | Society for Immunotherapy of Cancer Meeting - Abstract Number No - 1166 |
| 2023-09-10 09:00 am | European Association of Nuclear Medicine Congress |
| 2023-09-08 | European Association of Nuclear Medicine Congress - Poster Number: EP-0608 |
| 2023-09-06 07:00 pm | Society of Hematologic Oncology Meeting - Poster No:AML-521 |
| 2023-09-06 07:00 pm | Society of Hematologic Oncology Meeting - Poster No:AML-530 |
| 2023-09-06 07:00 pm | Society of Hematologic Oncology Meeting - Poster No:AML-502 |
| 2023-07-27 12:30 pm | Targeted Radiopharmaceuticals Summit |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 1,14 1,21 -5.77% | 1,03 1,85 -44.38% | 0,08 0,22 -62.55% | 0,19 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -21,0 -22,1 5.15% | -24,4 -23,7 -3.12% | -33,4 -24,7 -35.24% | -51,1 -57,2 10.61% | -60,5 |
|
EBIT Million USD | Released Forecast Spread | -22,1 -24,2 8.7% | -22,4 -22,0 -1.89% | -25,0 -23,6 -5.92% | -34,1 -31,7 -7.53% | -51,9 -55,6 6.67% | -57,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -21,9 -24,1 9.2% | -22,2 -21,5 -3.15% | -24,8 -23,8 -3.9% | -33,0 -30,7 -7.49% | -48,8 -54,4 10.22% | -59,1 |
|
Net income Million USD | Released Forecast Spread | -21,9 -24,1 9.19% | -22,2 -21,5 -3.16% | -24,8 -23,8 -3.9% | -33,0 -30,7 -7.49% | -48,8 -54,4 10.22% | -59,1 |
|
EPS USD | Released Forecast Spread | -4,50 -4,80 6.25% | -1,83 -1,77 -3.39% | -1,20 -1,16 -3.45% | -1,37 -1,27 -7.66% | -1,83 -2,04 10.09% | -1,87 |
| Announcement Date | 08/05/20 | 31/03/21 | 25/03/22 | 31/03/23 | 29/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,94 0,00 - | 0,05 0,93 -95.14% | 0,05 0,73 -93.79% | 0,00 1,03 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,46 - | 0,08 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 2,88 | 41,4 |
|
EBITDA Million USD | Released Forecast Spread | -5,03 -8,00 37.16% | -7,67 -4,40 -74.32% | -9,58 -5,50 -74.15% | -11,1 -1,90 -485.79% | -11,4 -10,3 -10.7% | -15,4 -12,4 -24.46% | -14,2 -11,0 -28.65% | -10,1 -15,6 34.97% | -9,38 -13,0 27.84% | -14,3 | -15,8 | -17,4 | ||
|
EBIT Million USD | Released Forecast Spread | -5,16 -7,05 26.8% | -7,85 -5,35 -46.73% | -9,80 -7,66 -28% | -11,3 -8,21 -37.49% | -11,6 -10,7 -8.09% | -15,6 -12,0 -30.54% | -14,4 -13,9 -3.15% | -10,3 -14,3 27.72% | -9,60 -15,1 36.46% | -16,0 | -16,5 | -17,1 | -17,0 | 21,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -5,13 -7,61 32.64% | -7,77 -4,40 -76.52% | -9,47 -7,62 -24.34% | -10,6 -8,35 -27.51% | -11,0 -10,9 -1.37% | -15,2 -11,4 -32.88% | -13,3 -12,3 -7.83% | -9,32 -14,3 34.95% | -8,67 -14,9 41.96% | -15,8 | -16,3 | -16,9 | -17,0 | 21,1 |
|
Net income Million USD | Released Forecast Spread | -5,13 -7,61 32.64% | -7,77 -4,40 -76.52% | -9,47 -7,62 -24.34% | -10,6 -8,35 -27.51% | -11,0 -10,9 -1.37% | -15,2 -11,4 -32.88% | -13,3 -12,3 -7.83% | -9,32 -14,3 34.95% | -8,67 -14,9 41.96% | -15,8 | -16,3 | -16,9 | -17,0 | 18,1 |
|
EPS USD | Released Forecast Spread | -0,23 -0,34 32.35% | -0,33 -0,18 -83.33% | -0,38 -0,30 -28.81% | -0,43 -0,33 -30.3% | -0,43 -0,42 -1.78% | -0,58 -0,44 -32.57% | -0,49 -0,47 -5.38% | -0,33 -0,52 36.84% | -0,31 -0,52 40.38% | -0,55 | -0,54 | -0,54 | -0,50 | 0,44 |
| Announcement Date | 13/05/22 | 12/08/22 | 14/11/22 | 31/03/23 | 15/05/23 | 14/08/23 | 02/11/23 | 29/03/24 | 26/04/24 | - | - | - | - | - |
More events
Past sector events for Actinium Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ATNM Stock
- Calendar Actinium Pharmaceuticals, Inc.
